Biomolecules

[1] Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

[2] antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease

[3] context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency

[4] Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.

[5] Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

[6] Application of hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for the retention and sensitivity studies of antisense oligonucleotides.

[7] Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

[8] antisense oligonucleotide mediated splice correction of a deep intronic mutation in opa1

[9] lrrk2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a parkinson’s disease mouse model

[10] antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease

[11] from cryptic toward canonical pre-mrna splicing in pompe disease: a pipeline for the development of antisense oligonucleotides

[12] cholesterol-lowering action of bna-based antisense oligonucleotides targeting pcsk9 in atherogenic diet-induced hypercholesterolemic mice

[13] The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy